🇺🇸 FDA
Patent

US 8084415

Uteroglobin in the treatment of IGA mediated nephropathy

granted A61KA61K38/1709A61P

Quick answer

US patent 8084415 (Uteroglobin in the treatment of IGA mediated nephropathy) held by The United States of America as Represented by the Secretary of the Department of Health and Human Services expires Mon Dec 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Grant date
Tue Dec 27 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 22 2031 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K38/1709, A61P, A61P11/00, A61P29/00